Даваа–Баасан 08:30–20:00 · Бямба 09:00–16:00
Now showing 1 - 9 of 9
  • Some of the metrics are blocked by your 
    Item type:Publication,
    SARS-CoV-2 вирусын түгээмэл илэрч буй мутациуд
    (2021-09-01)
    Ө.Хулан
    ;
    М.Халиун
    ;
    М.Батхишиг
    ;
    Э.Билгүүн
    ;
    Т.Балжинням
    Амьсгалын замын цочмог хамшинжийг үүсгэгч коронавирусээр (SARS-CoV-2) үүсгэгдсэн КОВИД-19 өвчний (COVID-19) халдварын цар тахал нь Хятадын Хубей мужийн Ухань хотод 2019 оны 12 сард анх дэгдсэн. SARS-CoV-2 нь Betacoronavirus-ийн бүлэгт хамаарагддаг бөгөөд генийн болон фенотипийн бүтцээрээ SARSCoV-79.5% гомологи, MERS-CoV-50% гомологи буюу ижил байна. 2019 оны сүүлээс КОВИД-19 өвчний халдварын тархалт дэлхий даяар хяналтгүй тархсан ба энэ нь вирусын шинэ мутаци үүсэх цаашлаад илүү хор хөнөөлтэй болон эмчилгээнд тэсвэртэй вирусын омог үүсэх нөхцөлийг бүрдүүлж байна. Вирусын омог тогтвортойгоор мутацид орсноор дэлхий даяар вирусын шинэ мутацийн омог тархаж эхэлсэн байна. SARS-CoV-2-ийн шинэ хувилбар нь бусад вирусын хувилбарыг бодвол хурдан, хялбар тархаж байгаа нь уг өвчний халдварын тохиолдлыг ихсэхэд хүргэж байна. SARS-CoV-2 олон тооны хувилбарууд дэлхийн дахинд тархсаар байна. 2020 оны намар Англи улсад B.1.1.7 гэх шинэ мутаци бүхий том хувилбар гарч ирэв. Энэ шинэ хувилбар нь дэлхийн маш олон оронд илэрсэн. Өмнөд Африкт B.1.351 гэж нэрлэгдэх өөр нэг хувилбар гарсан бөгөөд энэ нь B.1.1.7 хамааралгүйгээр үүссэн байна. Энэ хувилбар нь зарим B.1.1.7 агуулсан мутацид оролцдог. Бразилд гарсан Р.1 хувилбар нь 17 төрлийн мутаци агуулдаг түүнчлэн сэртэнт уураг нь рецептор холбогдох 3 домэйнийг агуулдаг. Шинэ мутаци ба шинэ хувилбар нь өвөрмөц оношилгооны шинжилгээгээр илрүүлэхээс зайлсхийх чадвар нь хүмүүст халдвар илүү хурдан тархах, хүнд өвчин үүсгэх зэрэг үр дагавартай байна.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Монгол Улсад шинэ короновирусын (COVID-19) халдвар батлагдсан анхны тохиолдлын компьютерт томографийн оношилгоо
    (2020-05-01)
    С.Роломжав
    ;
    М.Мөнгөнхуяг
    ;
    Д.Эрдэнэсүрэн
    ;
    Ц.Отгонтуяа
    ;
    Б.Эрдэнэбулган
    Цээжний томографийг COVID-19 уушгины хатгалгааны уушигны хүндийн зэргийг үнэлэхэд ашигладаг. Бид COVID-19 уушгины үрэвсэлтэй хавсарсан цээжний томографийн өөрчлөлтийн анхны оношлогооноос өвчтөний бие сэргэх хүртэл өөрчлөлтийг тодорхойлохыг зорилоо. Энэхүү ретроспектив шинжилгээнд RT-PCR-аар батлагдсан COVID-19 халдвартай өвчтөнүүдийг хамруулсан болно. Өвчний явцын аль ч үед амьсгалын замын хүнд хямралтай болон хүчилтөрөгч зайлшгүй хэрэгцээтэй өвчтөнүүдийг оруулаагүй болно. Давтан цээжний томографийг ойролцоогоор 7 хоногийн интервалтайгаар авсан. COVID19-ийн халдвараас эдгэрсэн өвчтөнүүдэд цээжний СТ-ийн хувьслын дөрвөн үе шатыг тогтоосон: эрт үе шат (0-4 хоног); дэвшилтэт үе шат (5-8 хоног); оргил үе (10-13 хоног); шингээлтийн үе шат (≥14 хоног). Цээжний КТГ-ийн шинжилгээнд короновирусын халдварын үед бүүдгэр шилний шинж, нэвчдэс болон плеврийн зузаарлын өөрчлөлт илэрч байна.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    COVID-19 халдварын полимеразын гинжин урвалын шинжилгээг нэвтрүүлсэн дүн
    (2020-05-01)
    Д.Баяржаргал
    ;
    ;
    Г.Уранбилэг
    ;
    Ц.Уянга
    ;
    Нуклейн хүчлийг олшруулах оношлогооны арга нь коронавирус 2 (SARS-CoV-2) вирүсээр үүсгэгдэх амьсгалын замын хурц үрэвслийг илрүүлэх анхдагч оношлогоо нь юм. Коронавирус 2 (SARS-CoV-2) вирусээр үүсгэгдэх амьсгалын замын хурц үрэвсэлт хамшинжийн халдварын лабораторийн оношлогоонд амьсгалын замаас авсан сорьцонд вирусийн нуклейн хүчлийг олшруулах шинжилгээ хийж байна. УХТЭ-н Нэгдсэн Лабораторийн Тасаг covid-19 халдварыг илрүүлэх түргэвчилсэн тестийн аргаар болон ПГУ-ын баталгаажуулах шинжилгээг нэвтрүүлэх зайлшгүй шаардлага урган гарч байна. COVID-19 халдварын баталгаажуулах ПГУ-ын шинжилгээг нэвтрүүлэх зорилго тавьсан. Зорилгын хүрээнд лабораторийн боловсруулсан шинжилгээний САЗ, АЗ дагуу сорилыг хийж гүйцэтгэв. Судалгааны дүнд САЗ, АЗ боловсруулсан. Түргэвчилсэн оношлуураар 23 сорьцонд шинжилгээг хийж коронавирус 2 (SARS-CoV-2)-ийн эсрэгөрөгч, эсрэгбие бүгд сөрөг гарсан. Xpert Xpress SARS-CoV-2 оношлуураар 11 сорьцыг шинжилсэн ба SARS-CoV-2 вирусын РНХ тодорхойлогдоогүй, шинжилгээний хариу бүгд сөрөг гарсан. Богино хугацаанд, аюулгүй, баталгаажсан аргаар COVID-19 халдварын оношлогоог хийх боломжтойг баталлаа.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial
    (Elsevier BV, 2025-11)
    Batmunkh, Tsetsegsaikhan
    ;
    Neal, Eleanor F G
    ;
    Amraa, Otgonjargal
    ;
    Mazarakis, Nadia
    ;
    Altangerel, Bolor
    BACKGROUND: COVID-19 vaccine booster doses counteract waning immunity and vaccine escape by emerging variants. We evaluated long-term immunogenicity and safety of fractional and standard BNT162b2 vaccine booster doses in Mongolia. METHODS: In this randomised, controlled, non-inferiority trial, adults primed with two doses of ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac were randomised (1:1) to receive a 15 μg (fractional dose) or 30 μg (standard dose) BNT162b2 booster. Geometric mean ratios (GMR) of IgG and surrogate virus neutralising test (sVNT) levels (Wuhan-Hu-1 and Omicron BA.1) were compared over 12 months. SARS-CoV-2 infections, and adverse and serious adverse events (SAEs), were documented. CLINICALTRIALS: gov Identifier: NCT05265065. RESULTS: Of 601 participants randomised between May 27th and September 30th, 2022, 2 (0.3 %) were lost to follow-up and 19 (3.2 %) withdrew by 12 months. IgG levels declined from 28 days to six months, stabilising thereafter. At 12 months, IgG levels were lower in the fractional compared with the standard arm for ChAdOx1-S primed participants (GMR 0.78 [95 % CI 0.63-0.96], p = 0.017). At six and 12 months, the median sVNT inhibition percentages were comparable by study arm and priming strata. Documented SARS-CoV-2 infections occurred in 25 participants (fractional dose arm n = 12; standard dose arm n = 13). From 28 days, 228 undocumented infections (≥ 1.2-fold IgG increase) occurred (fractional arm n = 112; standard arm n = 116). SAEs (n = 41) were balanced between arms, with no severe vaccine-related AEs or SAEs reported. CONCLUSIONS: 15 μg and 30 μg BNT162b2 boosters demonstrated comparable immunogenicity and favourable safety. 15 μg BNT162b2 booster doses may improve vaccine acceptability due to lower reactogenicity.
    Scopus© Citations 3
  • Some of the metrics are blocked by your 
    Item type:Publication,
    A Randomized Trial of Vitamin D Supplementation and COVID-19 Clinical Outcomes and Long COVID: The Vitamin D for COVID-19 Trial
    (2026-04) ;
    Cook, Kaitlyn A
    ;
    Khudyakov, Polyna
    ;
    ;
    BACKGROUND: Data from randomized controlled trials of vitamin D3 supplementation in modifying the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are sparse. OBJECTIVES: We evaluated the effect of vitamin D3 supplementation on healthcare utilization and other clinical outcomes among adults with coronavirus disease 2019 (COVID-19) and their close contacts. METHODS: We conducted a parallel 2-group randomized controlled double-blinded trial targeting free-living adults in the United States and Mongolia. Index participants with newly diagnosed COVID-19 were cluster-randomized with up to one of their cohabiting contacts either to an oral vitamin D3 loading dose of 9600 IU/d for 2 d followed by 3200 IU/d for 4 wk or to placebo. Participants completed weekly questionnaires on healthcare utilization, disease severity, and long COVID (index participants) or new SARS-CoV-2 infection (household contacts). The primary outcome was ≥1 healthcare visits (including hospitalization) or death within 4 wk among the index participants. RESULTS: Index participants (n = 1747) were a median of 38.0 y old (IQR: 31.1-47.0), 65.6% female/other sex, 4.2% Black non-Hispanic, 4.8% Hispanic/Latinx, 43.2% Asian, 44.3% non-Hispanic White, and 44.9% vitamin D deficient or insufficient (25-hydroxyvitamin D3 <20 ng/mL). Baseline characteristics for the household contacts (n = 277) were similar. The 4-wk cumulative incidence of healthcare utilization in index participants did not significantly differ between the vitamin D3 (n = 863) and placebo (n = 884) groups [cumulative incidences, 0.28 compared with 0.29; odds ratio (OR), 0.97; 95% confidence interval (CI): 0.75, 1.24]. Similar nonsignificant results were observed for the prespecified secondary treatment and prevention outcomes, though per-protocol analyses showed a nonsignificant trend toward benefit of vitamin D3 on the prevalence of long COVID at 8 wk (OR, 0.78; 95% CI: 0.59, 1.03). No safety concerns were identified. CONCLUSIONS: Among adults with newly diagnosed SARS-CoV-2 infections, vitamin D3 supplementation did not significantly change the 4-wk cumulative incidence of healthcare utilization or COVID-19-related outcomes compared with placebo. Promising results for long COVID warrant further study. This study was registered at clinicaltrials.gov as NCT04536298. First registered on 1 September, 2020.
    Scopus© Citations 2
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial
    (Elsevier BV, 2024-01)
    Batmunkh, Tsetsegsaikhan
    ;
    Moore, Kerryn A
    ;
    Thomson, Helen
    ;
    Altangerel, Bolor
    ;
    Amraa, Otgonjargal
    BACKGROUND: COVID-19 vaccine booster doses restore vaccine effectiveness lost from waning immunity and emerging variants. Fractional dosing may improve COVID-19 booster acceptability and uptake and will reduce the per-dose cost of COVID-19 booster programmes. We sought to quantify the immunogenicity, reactogenicity, and safety of a half-dose BNT162b2 (Pfizer-BioNTech) booster relative to the standard formulation. METHODS: This randomised, controlled, non-inferiority trial recruited adults in Mongolia primed with a two-dose homologous ChAdOx1 nCov-19 (Oxford-AstraZeneca, n = 129 participants), BBIBP-CorV (Sinopharm (Beijing), n = 399), or Gam-COVID-Vac (Gamaleya, n = 70) schedule. Participants were randomised (1:1) to receive a 15 μg (half-dose) or 30 μg (full-dose) BNT162b2 booster. Participants and study staff assessing reactogenicity were blinded up to day 28. Co-primary endpoints were Wuhan-Hu-1 anti-spike S1 IgG seroresponse 28 days post-boosting and reactogenicity within 7 days of boosting. The non-inferiority margin for the absolute difference in seroresponse was -10%. Differences in seroresponse were estimated from logistic regression with marginal standardisation. Geometric mean ratios of IgG were also estimated. ClinicalTrials.gov Identifier: NCT05265065. FINDINGS: Between May 27th and September 30th, 2022, 601 participants were randomized to full-dose BNT162b2 (n = 300) or half-dose (n = 301). 598 were included in safety analyses, and 587 in immunological analyses. The frequency of grade 3-4 reactions was similar between arms (half-dose: 4/299 [1.3%]; full-dose: 6/299 [2.0%]). Across all severity grades, half-dose recipients reported fewer local and systemic reactions (60% versus 72% and 25% versus 32%, respectively). Seroresponse was 84.7% (250/295) and 86.6% (253/292) in the half-dose and full-dose arms, respectively (Difference: -2.8%; 95% CI -7.7, 2.1). Geometric mean IgG titres were similar in those receiving full and half-dose boosters for the ChAdOx1 and BBIBP-CorV primed groups, but lower in the half-dose arm in Gam-COVID-Vac-primed participants (GMR: 0.71; 95% CI 0.54, 0.93). INTERPRETATION: Half-dose BNT162b2 boosting elicited an immune response that was non-inferior to a full-dose, with fewer reactions, in adults primed with ChAdOx1 nCov-19 or BBIBP-CorV. Half-dose boosting may not be suitable in adults primed with Gam-COVID-Vac. Half-dose BNT162b2 boosting may be considered in populations primed with ChAdOx1 nCov-19 or BBIBP-CorV. FUNDING: Coalition for Epidemic Preparedness Innovations (CEPI).
    Scopus© Citations 11
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Fractional BNT162b2 boosters induce durable immune responses after non-mRNA priming in Mongolia: a randomised controlled trial
    (2026)
    Batmunkh, Tsetsegsaikhan
    ;
    Neal, Eleanor Fg
    ;
    Amraa, Otgonjargal
    ;
    Mazarakis, Nadia
    ;
    Altangerel, Bolor
    INTRODUCTION: COVID-19 boosters restore waning immunity. After demonstrating non-inferiority of 15 μg versus 30 μg BNT162b2 at 28 days in Mongolian adults, we assessed 24-month immunogenicity and safety. METHODS: In this randomised, controlled trial, adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac were assigned (1:1) to 15 μg or 30 μg BNT162b2. Anti-spike IgG, surrogate virus neutralisation (sVNT) against Wuhan-Hu-1 and Omicron BA.1, and interferon-gamma (IFN-γ) release assays (Ag1/Ag2) were assessed to 24 months. SARS-CoV-2 infections and serious adverse events (SAEs) were recorded. ClinicalTrials.gov: NCT05265065. RESULTS: Of 601 participants, 520 (86.5%) completed follow-up. IgG and IFN-γ responses were comparable between arms at 24 months (IgG geometric mean ratio (GMR) 1.06 [95% CI 0.95-1.18]; Ag1 GMR 1.17 [95% CI 0.82-1.66]; Ag2 GMR 1.06 [95% CI 0.73-1.54]). Median sVNT inhibition remained high (Wuhan-Hu-1 88% [interquartile range (IQR) 86-90]; Omicron BA.1 85% [IQR 70-88]). Twenty-eight SARS-CoV-2 infections occurred. Fifty-three SAEs were balanced by study arm, and none were vaccine related. DISCUSSION: Equivalent immunity and safety from 15 μg and 30 μg BNT162b2 boosters support fractional dosing as a cost-saving strategy. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/study/NCT05265065, identifier NCT05265065.
    Scopus© Citations 2
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Molecular epidemiology of SARS-CoV-2 in Mongolia, first experience with nanopore sequencing in lower- and middle-income countries setting
    (Wiley, 2023-12) ; ; ; ;
    Burged, Natsagdorj
    BACKGROUND: Coronavirus disease (COVID-19) has had a significant impact globally, and extensive genomic research has been conducted on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage patterns and its variants. Mongolia's effective response resulted in low prevalence until vaccinations became available. However, due to the lack of systematically collected data and absence of whole genome sequencing capabilities, we conducted a two-stepped, nationally representative molecular epidemiologic study of SARS-CoV-2 in Mongolia for 2020 and 2021. METHODS: We used retrospective analysis of stored biological samples from November 2020 to October 2021 and a variant-specific real-time reverse transcription polymerase chain reaction (RT-PCR) test to detect SARS-CoV-2 variants, followed by whole genome sequencing by Nanopore technology. Samples were retrieved from different sites and stored at -70°C deep freezer, and tests were performed on samples with cycle threshold <30. RESULTS: Out of 4879 nucleic acid tests, 799 whole genome sequencing had been carried out. Among the stored samples of earlier local transmission, we found the 20B (B.1.1.46) variant predominated in the earlier local transmission period. A slower introduction and circulation of alpha and delta variants were observed compared to global dynamics in 2020 and 2021. Beta or Gamma variants were not detected between November 2020 and September 2021 in Mongolia. CONCLUSIONS: SARS-CoV-2 variants of concerns including alpha and delta were delayed in circulation potentially due to public health stringencies in Mongolia. We are sharing our initial experience with whole genome sequencing of SARS-CoV-2 from Mongolia, where sequencing data is sparse.
    Scopus© Citations 1
  • Some of the metrics are blocked by your 
    Item type:Publication,
    One-year antibody kinetics and effectiveness of a BNT162b2 booster after four primary COVID-19 vaccination regimens in Mongolia
    (2026-09)
    Bazarjav, Purevbat
    ;
    Erdene-Ochir, Tseyenkhorloo
    ;
    Sandagdorj, Ankhbayar
    ;
    Enkhtuvshin, Altansukh
    ;
    Enkhbayar, Purevjargal
    BACKGROUND: Waning immunity after primary COVID-19 vaccination and the widespread use of heterogeneous vaccine platforms have created uncertainty regarding the durability of protection following booster vaccination. Mongolia implemented a mixed-platform vaccination program and deployed BNT162b2 as a booster. We evaluated the immunogenicity, effectiveness, and safety of a BNT162b2 booster following four primary vaccination regimens with 12 months follow-up. METHODS: In this prospective observational study in Ulaanbaatar, Mongolia, adults (≥18 years) who had completed a homologous two-dose primary series with BBIBP-CorV, ChAdOx1 nCoV-19, Gam-COVID-Vac, or BNT162b2 received a BNT162b2 booster a median of 189 days (IQR 186-215) after the second dose and were grouped according to their primary vaccination regimen. Humoral immune responses (anti-SARS-CoV-2 N/S1-RBD IgG, S-RBD IgG, and neutralizing antibodies) were measured at baseline and at multiple time points up to 12 months after booster vaccination. Reactogenicity was monitored for 28 days. SARS-CoV-2 infection was ascertained by a positive antigen/lateral-flow test and/or RT-PCR. VE was estimated for prespecified follow-up intervals by comparing the risk of SARS-CoV-2 infection in each boosted group with that in an unvaccinated comparison group. FINDINGS: Among 311 participants (mean age 41.88 years [SD 13.64]; 175 [56.27%] women and 136 [43.73%] men), antibody responses peaked at day 14 and declined through day 365 in all groups. At day 14, total antibody concentrations were highest in BNT + BNT (385.03 U/mL) and lowest in Gam + BNT (341.74 U/mL). S-RBD IgG at day 14 was highest in BNT + BNT (967.0 ng/mL) and lowest in BBIBP+BNT (863.70 ng/mL). Neutralizing antibodies at day 14 were highest in BNT + BNT (368.13 AU/mL) and BBIBP+BNT (336.70 AU/mL). During follow-up, 64 participants acquired SARS-CoV-2 infection and 15 (23.44%) were admitted to hospital. Reactogenicity was predominantly mild-to-moderate, and laboratory parameters were generally within acceptable ranges. Vaccine effectiveness declined from 1 month to 12 months: BBIBP+BNT 90.54% (95% CI 59.71-97.78) to 71.17% (39.66-86.23); ChAd+BNT 84.97% (49.75-95.51) to 52.59% (8.61-75.41); Gam + BNT 89.68% (23.95-98.60) to 63.84% (15.10-84.60); BNT + BNT 91.89% (40.06-98.90) to 72.29% (34.37-88.30). INTERPRETATION: A BNT162b2 booster following diverse primary COVID-19 vaccination regimens induced strong humoral responses that declined over 12 months and showed an acceptable reactogenicity profile. VE against SARS-CoV-2 infection was highest soon after boosting and lower later in follow-up. Although antibody levels and VE showed similar temporal patterns, these findings should be interpreted as complementary outcomes rather than evidence of a direct causal relationship or a formal immunological correlate of protection.